Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer
(NSCLC). Oligometastasis has been associated with better prognosis than widespread …

Simple Summary A significant number of patients diagnosed with non-small cell lung cancer
(NSCLC) will have a metastatic Stage IV disease at presentation. Among those, patients with …

PURPOSE This multicenter, randomized, phase III clinical trial (Northern Radiation
Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small …

Cure of cancer is a sensitive and multidimensional concept that is challenging to define,
difficult to assert at the individual patient level, and often surrounded by controversy. The …

Lung cancer is the second most common cancer worldwide and the leading cause of cancer-
related fatalities, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung …

The prefix “oligo” comes from the Greek olígos, meaning “little, small, few.” 1 As originally
proposed by Hellman and Weichselbaum in 1995 on the basis of clinical and historic …

Background: The primary aim of this phase II clinical study was to assess the safety and
efficacy of combining anlotinib, etoposide, and platinum-based drugs as a first-line treatment …

Oligometastatic non-small cell lung cancer (NSCLC) is an intermediate state between
localized and widely metastatic NSCLC, where systemic therapy in combination with …